Skip to main content

Piramal Pharma Selects Merit's FlexiPOD Platform for Antibody Drug Conjugate Facility

Published 2/25/2022
Piramal Pharma Solutions - Antibody Drug Conjugate Facility

Piramal Pharma Solutions broke ground in February of 2022 on a £45 million antibody drug conjugate (ADC) facility in Grangemouth, Scotland. Accommodating both manufacturing and aseptic fill/finish operations, the structure will provide additional capacity for the creation of targeted cancer treatments and other innovative therapies. Representing an expansion of Piramal's existing ADC campus, the project is being delivered by Merit using its FlexiPOD V4.0 platform. Enabling design, production, installation, and validation to be completed in just 16 months, the FlexiPOD solution is a hybrid of traditional shell-and-core and offsite construction methodologies. Requiring less space for mechanical infrastructure and distributed services, the modular units offer enhanced technical and energy performance in a condensed footprint to achieve cost savings in both initial capital investment and ongoing maintenance. Completion is expected in the third quarter of 2023. Piramal Pharma Solutions is based in Mumbai, India.